Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.



Georgia Fogden-King's Articles

Innovation Through Insight

Boost your productivity through STFC’s Bridging for Innovators programme

J A Kemp Expands in Cambridge

J A Kemp has relocated its Cambridge office today, 14 May, to larger, more modern premises on Capital Park. The firm is more than doubling its office space in Cambridge.

High Throughput Gene Expression Analysis Service

AMSBIO, a global provider of gene editing and personalized medicine technologies, has launched a service for high throughput gene expression analysis. 

UK Government offer £2,500 funding support for UK exhibitiors

The UK Government and the Department for International Trade (DIT) are therefore keen to support UK exhibitors at the event, by offering funding support in the form of TAP Grants* at the value of £2,500.

Aptus Clinical - Ready for Growth

It’s only May and it has already been quite a year for Aptus Clinical. We have added several exceptional individuals to our team, given a well-deserved internal promotion and restructured to ensure efficient project management, seamless client liaison and access to our exceptional talent is at the heart of the client experience.

Foresight makes £3.5m growth capital investment into Mologic

Investment to support launch of sepsis, COPD and infectious disease diagnostics and international expansion of Contract Research business.

Chronos Therapeutics Announces Positive Pre-Clinical Proof of Concept Studies for its Orexin-1 Antagonist Project Initially Targeting Binge Eating Disorder

Chronos Therapeutics Ltd (Chronos) the private biotech company focused on ageing diseases, brain and nervous system disorders, announced today that the lead compound in its addiction programme, CT-010018 an orexin-1 antagonist, demonstrated positive pre-clinical proof of concept (POC) results in an in vivo model of binge eating disorder (BED).

 Business Development Manager (Energy)

Do you have experience of selling energy procurement contracts into the I&C retail UK Energy Industry? A leading Gas and Electricity consultants is seeking a Business Development Manager to join their Coventry based team, to enhance the company’s position in terms of both new sales and margin growth

Isogenic Cell Lines for Cancer Research

AMSBIO has introduced a new range of over 400 Isogenic cell lines that provide a reliable and efficient alternative to traditional human disease models.

Crescendo raises $70M to trial bispecific T-cell engager

Crescendo Biologics has raised $70 million (€57 million) to take its lead bispecific T-cell engager into the clinic. The financing equips Crescendo to show whether its vision for dialing up T-cell activity in the tumor microenvironment translates into humans.

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.